Journal of Rheumatic Diseases

Table. 4.

Comparison of Fibromyalgia patients by insomnia severity

Severity of insomnia Grade 1∼2 (n=19) Grade 3∼4 (n=28) p-value
Age (yr) 55.9±8.9 52.4±8.5 0.177§
Sex 0.060
Male 3 (15.8) 0 (0)
Female 16 (84.2) 28 (100)
Fibromyalgia duration (mo) 67.0±50.9 95.1±61.0 0.104§
Widespread Pain Index 10.2±4.8 10.6±5.3 0.795§
Symptom Severity Score 6.3±2.4 7.9±1.9 0.019
VAS of pain* 53.3±16.3 67.7±16.9 0.116
Fibromyalgia Impact Questionnaire 53.4±18.3 69.2±15.0 0.002§
SF-36
Physical functioning 43.2±19.8 38.2±21.3 0.426§
Role limitations due to physical condition 43.4±41.5 14.3±21.0 0.013
Bodily pain 46.6±17.6 29.2±14.9 0.001
General health 38.7±13.2 28.0±12.7 0.008§
Vitality (energy and fatigue) 35.8±16.5 20.9±9.2 0.003
Social functioning 57.9±15.7 39.3±22.7 0.003§
Role limitations due to emotional condition 66.7±44.4 20.2±36.7 0.001
Mental health 53.1±16.7 32.3±13.0 <0.001§
Health change 40.8±27.9 23.3±25.4 0.028
Associated symptoms
Headache 15 (78.9) 26 (92.9) 0.204
Irritable bowel syndrome 2 (10.5) 4 (14.3) 1
Tinnitus 11 (57.9) 11 (39.3) 0.210
Used medication 14 (73.7) 20 (71.4) 0.865

Values are presented as mean±standard deviation or number (%). SF-36: Short-form Health Survey. *The Visual Analog Scale (VAS) of pain intensity is a 100-point linear gauge in which 0=no pain and 100=worst pain imaginable. Satisfies the Rome IV diagnostic criteria. Medication including selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor/ Pregabalin. §One-way ANOVA test; Kruskal-Wallis test; chi-square test.

J Rheum Dis 2021;28:31~37 https://doi.org/10.4078/jrd.2021.28.1.31
© J Rheum Dis